Compare SLAB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLAB | LNTH |
|---|---|---|
| Founded | 1996 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.5B |
| IPO Year | 2000 | 2014 |
| Metric | SLAB | LNTH |
|---|---|---|
| Price | $217.47 | $99.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $163.13 | $87.00 |
| AVG Volume (30 Days) | 335.3K | ★ 977.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.61 | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | ★ $491,625,000.00 | $343,374,000.00 |
| Revenue This Year | $20.49 | N/A |
| Revenue Next Year | $16.65 | $14.19 |
| P/E Ratio | ★ N/A | $55.18 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $115.51 | $47.27 |
| 52 Week High | $219.33 | $102.66 |
| Indicator | SLAB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 61.06 | 67.78 |
| Support Level | $215.02 | $91.65 |
| Resistance Level | $218.68 | N/A |
| Average True Range (ATR) | 1.12 | 3.13 |
| MACD | -0.24 | 0.17 |
| Stochastic Oscillator | 66.82 | 66.35 |
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.